Treatment and prevention of P. aeruginosa infections using coformycin analogs
US-9522159-B2 · Dec 20, 2016 · US
Treatment of H. pylori infections using MTAN inhibitors
US10118928B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10118928-B2 |
| Application number | US-201515118113-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2015 |
| Priority date | Feb 12, 2014 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of treating infections due to Helicobacter pylori ( H. pylori ), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5′-methylthioadenosine nucleosidase) to the subject, where the inhibitors have the structure
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a Helicobacter pylori ( H. pylori ) infection in a subject comprising administering to the subject a compound in an amount effective to inhibit growth of H. pylori , wherein the compound has the formula wherein R is Q or CH 2 SQ 1 , wherein Q is C1-C9 alkyl, aryl, heteroaryl, aralkyl, or C4-C7 cycloalkyl, where Q is optionally substituted with one or more halogen, OH and/or NH 2 groups, and wherein Q 1 is C4-C9 alkyl, aryl, heteroaryl, aralkyl, or C4-C7 cycloalkyl, where Q 1 is optionally substituted with one or more halogen, OH and/or NH 2 groups, or a pharmaceutically acceptable salt thereof, or an ester thereof. 2. The method of claim 1 , wherein R is Q. 3. The method of claim 1 , wherein R is CH 2 SQ 1 . 4. The method of claim 1 , wherein Q is C1-C9 alkyl. 5. The method of claim 1 , wherein Q or Q 1 is C4-C7 cycloalkyl. 6. The method of claim 1 , wherein Q or Q 1 is aryl. 7. The method of claim 1 , wherein Q or Q 1 is heteroaryl. 8. The method of claim 1 , wherein Q or Q 1 is aralkyl. 9. The method of claim 1 , wherein Q or Q 1 is aryl, heteroaryl or aralkyl substituted with a halogen. 10. The method of claim 1 , wherein R is Q, wherein Q is C2-C9 linear alkyl, aryl, heteroaryl, aralkyl, or C4-C7 cycloalkyl, and wherein Q is optionally substituted with one or more halogen, OH and/or NH 2 groups. 11. The method of claim 9 , wherein the halogen is at an ortho, meta or para position. 12. The method of claim 1 , wherein the halogen is Cl, F, Br or I. 13. The method of claim 1 , wherein Q is C3-C9 linear alkyl or heteroaryl. 14. The method of claim 1 , wherein the compound is selected from the group consisting of or a pharmaceutically acceptable salt thereof, or an ester thereof. 15. A method of treating a Helicobacter pylori ( H. pylori ) infection in a subject comprising administering to the subject a compound in an amount effective to inhibit growth of H. pylori , wherein the compound is selected from the group consisting of or a pharmaceutically acceptable salt thereof, or an ester thereof. 16. The method of claim 1 , wherein the compound is administered in an amount that is effective to inhibit H. pylori 5′-methylthioadenosine nucleosidase (MTAN). 17. The method of claim 1 , wherein the compound inhibits growth of H. pylori but does not inhibit the growth of one or more bacterium selected from the group consisting of E. coli, V. cholerae, S. aureus, K. pneumoniae, S. flexneri, S. enterica and P. aeruginosa. 18. The method of claim 17 , wherein the compound does not inhibit the growth of all of E. coli, V. cholerae, S. aureus, K. pneumoniae, S. flexneri, S. enterica and P. aeruginosa. 19. The method of claim 1 , wherein the compound is more effective in inhibiting growth of H. pylori than amoxicillin, metronidazole or tetracyclin. 20. The method of claim 1 , wherein the subject has a peptic ulcer. 21. The method of claim 1 , wherein the subject has a gastric ulcer or a duodenal ulcer. 22. The method of claim 1 , wherein the compound is administered orally.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Cross-Sectional Technologies · mapped topic
Cross-Sectional Technologies · mapped topic
Cross-Sectional Technologies · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10118928B2 cover?
- Methods of treating infections due to Helicobacter pylori ( H. pylori ), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5′-methylthioadenosine nucleosidase) to the subject, where the inhibitors have the structure
- Who is the assignee on this patent?
- Albert Einstein College Medicine Inc, Victoria Link Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).